January 21, 2012Journal of Hypertension
Inhibition of the renin–angiotensin–aldosterone system
Key result
Dual blockade of the renin-angiotensin-aldosterone system using ACE inhibitors and ARBs is not supported by current evidence, though other combinations remain under investigation.
Why the study?
Does dual blockade of the renin-angiotensin-aldosterone system provide advantages in patients with arterial hypertension and diabetes?
Population
Patients with arterial hypertension and diabetes
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
ACEi/ARB dual blockade lacks support in hypertension with diabetes; leaves open other RAAS combinations for prospective trials.
Structured PICO
Does dual blockade of the renin-angiotensin-aldosterone system provide advantages in patients with arterial hypertension and diabetes?
P
Population
Patients with arterial hypertension and diabetes
I
Intervention
Dual blockade of the renin-angiotensin-aldosterone system (e.g., combining ACE inhibitors, ARBs, direct renin inhibitors, or mineralocorticoid receptor antagonists)
This review highlights that while ACEi/ARB dual blockade is not supported by current evidence, other dual RAAS blockade strategies remain under investigation for hypertension and diabetes.
Cite This Study
Volpe et al. (2012) conducted a review in Arterial hypertension and diabetes. Dual blockade of the renin-angiotensin-aldosterone system was evaluated. Dual blockade of the renin-angiotensin-aldosterone system using ACE inhibitors and ARBs is not supported by current evidence, though other combinations remain under investigation.